Federal Register / Vol. 70, No. 210 / Tuesday, November 1, 2005 / Notices 65901 

SUPPLEMENTARY INFORMATION: PACHA 

was established by Executive Order 

12963, dated June 14, 1995, as amended 

by Executive Order 13009, dated June 

14, 1996. PACHA was established to 

provide advice, information, and 

recommendations to the President 

regarding programs and policies 

intended to (a) promote effective 

prevention of HIV disease, (b) advance 

research on HIV and AIDS, and (c) 

promote quality services to persons 

living with HIV disease and AIDS. 

PACHA was established to serve solely 

as an advisory body to the President and 

the Secretary of Health and Human 

Services. PACHA is composed of not 

more than 21 members. PACHA 

membership is determined by the 

Secretary from individuals who are 

considered authorities with particular 

expertise in, or knowledge of, matters 

concerning HIV/AIDS. 

The agenda for this meeting includes 

the following topics: HIV/AIDS 

prevention, care and treatment, and 

global HIV/AIDS issues. Time will be 

allotted during the meeting for public 

comment. 

Public attendance is limited to space 

available and pre-registration is required 

for both attendance and public 

comment. Any individual who wishes 

to attend and/or comment must register 

on-line at http://www.pacha.gov. 

Individuals who need special 

assistance, such as sign language 

interpretation or other reasonable 

accommodations, should indicate when 

registering on-line. 

Members of the public will have the 

opportunity to provide comments at the 

meeting. Public comment will be 

limited to three (3) minutes per speaker 

and to time available. Written 

testimony, not exceed five (5) pages, 

will be accepted by mail or facsimile at 

202/205–4986. 

Written testimony will not be 

accepted after 5 p.m., Wednesday, 

November 9, 2005. 

Dated: October 26, 2005. 

Joseph Grogan, 

Executive Director, Presidential Advisory 

Council on HIV/AIDS. 

[FR Doc. 05–21714 Filed 10–31–05; 8:45 am] 

BILLING CODE 4150–43–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Statement of Organization, Functions, 

and Delegations of Authority 

Part C (Centers for Disease Control 

and Prevention) of the Statement of 

Organization, Functions, and 

Delegations of Authority of the 

Department of Health and Human 

Services (45 FR 67772–76, dated 

October 14, 1980, and corrected at 45 FR 

69296, October 30, 1980, as amended 

most recently at 69 FR 77756, dated 

December 28, 2004) is amended to 

reorganize the National Center for HIV, 

STD, & TB Prevention. 

Section C–B, Organization and 

Functions, is hereby amended as 

follows: 

Delete in its entirety the following 

titles and functional statements: 

Division of AIDS, STD & TB Laboratory 

Research (CK7), Office of the Director 

(CK71), HIV, Immunology and 

Diagnostics Branch (CK72), HIV 

Immunology and Diagnostics Branch 

(CK73), Sexually Transmitted Infectious 

Diseases Branch (CK74), Tuberculosis/ 

Mycobacteriology Branch (CK75). 

Following the Training and Health 

Communication Branch (CK37), 

Division of STD Prevention (CK3), insert 

the following: 

Laboratory Reference and Research 

Branch, (CK38). (1) Performs research 

on the pathogenesis, genetics, and 

immunology of syphilis and other 

treponematoses, gonococcal and 

chlamydial infections, chancroid, 

genital herpes, donovanosis, bacterial 

vaginosis and trichomoniasis; (2) 

conducts and participates in clinical, 

field, and laboratory research to 

develop, evaluate, and improve 

laboratory methods used in the 

diagnosis and epidemiology of these 

sexually transmitted infections (STIs); 

(3) provides consultation and reference/ 

diagnostic services for these STIs; (4) 

conducts laboratory-based surveillance 

for and research on the genetics of 

antimicrobial resistance in Neisseria 

gonorrhoeae; (5) serves as the WHO 

International Collaborating Center for 

Reference and Research in Syphilis 

Serology; and (6) provides consultation 

and laboratory support for international 

activities. 

Following the International Research 

and Programs Branch (CK47), Division 

of Tuberculosis Elimination (CK4), 

insert the following: 

Mycobacteriology Branch (HCK48). (1) 

Provides laboratory support for 

epidemic investigations, surveillance 

activities, and special studies of 

tuberculosis and other mycobacteriacaused diseases; (2) administers 

contracts to provide Mycobacterium 

tuberculosis genotyping, maintains a 

national database of genotypes, and 

conducts operational research to 

implement genotyping; (3) develops and 

evaluates new methods to subtype 

mycobacteria for epidemiologic studies; 

(4) serves as primary CDC focus for 

diagnostic mycobacteriology laboratory 

services and for laboratory aspects of 

nontuberculosis Mycobacterium species 

and of Hansen disease (leprosy); (5) 

administers grants and cooperative 

agreements with states and others to 

upgrade laboratory activities and 

provide special services; (6) provides 

reference diagnostic services, 

consultation, technical assistance, and 

training to State, Federal, and municipal 

public health laboratories; (7) provides 

laboratory support, reference services, 

assessment, consultation, and training 

for CDC’s international tuberculosis 

activities; (8) develops, evaluates, or 

improves conventional and molecular 

methods for the detection, classification, 

identification, characterization, and 

susceptibility testing of mycobacteria 

and mycobacteria-caused diseases; (9) 

conducts studies to define the role of 

bacterial virulence factors, host factors, 

and pathogenic and immunologic 

mechanisms in disease processes and 

protective immunity and develops, 

evaluates, and improves immunologic 

methods for the diagnosis and 

prevention of mycobacteria-caused 

diseases; (10) develops tissue culture 

and animal models of mycobacteriacaused diseases and conducts studies on 

chemotherapy, immunotherapy, 

pathogenesis, pathology, and vaccines 

for mycobacteria-caused diseases; (11) 

conducts studies on the isolation, 

taxonomy, and ecology of mycobacteria 

and develops tests to identify new 

species; (12) conducts and supports 

studies to characterize newly emerging 

pathogenic species of Mycobacterium 

and associated diseases. 

Following the HIV Incidence and 

Case Surveillance Branch (CK56), 

Division of HIV, AIDS Prevention—

Surveillance and Epidemiology (CK5), 

insert the following: 

HIV and Retrovirology Laboratory 

Branch (HCK57). (1) Conducts studies of 

human immunodeficiency viruses 

(HIVs) and other human and zoonotic 

retroviruses, including the diseases they 

cause, their modes of transmission, and 

the means for their control through 

virus detection, isolation, and 

characterization by virologic, molecular, 

and cellular biologic methods; (2) 

65902 Federal Register / Vol. 70, No. 210 / Tuesday, November 1, 2005 / Notices 

collaborates with NCHSTP investigators 

to conduct HIV epidemiologic and 

surveillance studies worldwide 

particularly as they pertain to 

prevention and intervention strategies; 

(3) identifies and characterizes new HIV 

isolates and develops new screening 

tests for these isolates to determine their 

prevalence in various populations; (4) 

determines geotypic and phenotypic 

variations of HIVs that may affect 

pathogenesis, drug resistance, 

persistence, virulence, and 

transmissibility; (5) conducts and 

supports field epidemiologic 

investigations of the prevalence, 

distribution, trends, and risk factors 

associated with non-AIDS retroviral 

infections and associated diseases; (6) 

serves as a World Health Organization 

(WHO) Reference Center and as a 

member of the UNAIDS Virus Network 

to provide international consultation 

and technical assistance on laboratory 

procedures for HIV isolation, detection, 

and characterization; (7) develops and 

evaluates procedures for the isolation 

and characterization of HIV and for the 

detection of retroviral DNA or RNA 

from clinical samples; (8) provides 

training, reference testing, and reference 

reagents for virologic and molecular 

characterization of divergent HIVs for 

public health laboratories in the United 

States and WHO; (9) serves as a 

reference laboratory for the isolation of 

zoonotic retroviruses from clinical 

samples; (10) develops collaborations 

with other CDC and non-CDC scientists 

to promote scientific progress and 

accomplishments; and (11) collaborates 

with industry to promote 

commercialization of useful technology, 

methodologies, and reagents of public 

health importance. 

HIV Immunology and Diagnostic 

Laboratory Branch (HCK58). (1) 

Conducts basic and applied studies of 

microbial-host interactions that occur in 

infections, particularly infection with 

human immunodeficiency virus (HIV); 

(2) conducts basic and applied 

investigations of the immune cell 

interactions that occur in HIV infection 

as well as in related immunologic/ 

infectious diseases; conducts 

investigations of genetic traits of the 

host that influence the susceptibility, 

disease course, and immune response to 

infectious disease, particularly HIV 

diseases; (3) conducts studies related to 

the development, evaluation, 

improvement, and standardization of 

laboratory technologies uses for the 

diagnosis, surveillance, and monitoring 

of HIV infection both independently 

and in collaboration with the 

biotechnology industry; (4) performs 

HIV antigen and antibody testing plus 

related standardized assays in support 

of the diagnostic/surveillance/ 

epidemiologic requirements of CDCbased and CDC-affiliated studies of the 

HIV epidemic; (5) serves as a reference 

laboratory for State and local health 

departments; and (6) provides 

diagnostic services to other Federal 

agencies, the World Health 

Organization, CDC-affiliated academic 

centers, CDC-affiliated studies with 

other countries, and community 

organizations, as appropriate. 

Dated: April 1, 2005. 

William H. Gimson, 

Chief Operating Officer, Centers for Disease 

Control and Prevention (CDC). 

[FR Doc. 05–21672 Filed 10–31–05; 8:45 am] 

BILLING CODE 4160–18–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare and Medicaid 

Services 

Notice of Grant Award to MedCO 

Health Solutions, Inc., To Evaluate an 

Open-Source Project Entitled, ‘‘A 

Comparison of Multiple Methods to 

Incent Physicians To Adopt Electronic 

Prescribing Devices’’

AGENCY: Centers for Medicare and 

Medicaid Services (CMS), HHS. 

ACTION: Notice of Grant Award. 

SUMMARY: The Centers for Medicare and 

Medicaid Services has awarded a grant 

entitled, ‘‘A Comparison of Multiple 

Methods To Incent Physicians To Adopt 

Electronic Prescribing Devices’’ to 

Medco Health Solutions, Inc., 100 

Parsons Pond Drive, Franklin Lakes, NJ 

07417 in response to an unsolicited 

proposal. The period of performance is 

August 1, 2005 through July 31, 2006. 

The purpose of this grant is to fund an 

initial evaluation of the Southeastern 

Michigan e-Prescribing Initiative (SEMI) 

project. Through the use of eprescribing, this program is intended to 

reduce the costs associated with the use 

of prescription drugs, and improve 

safety for patients, including Medicare 

beneficiaries, associated with an 

estimated 6,000 targeted physicians/ 

prescribers in Southeastern Michigan. 

The project involves the active 

collaboration of multiple employers, 

insurance entities and care providers in 

eight counties in Southeastern 

Michigan. Partners include the Big 

Three automakers, Ford, General Motors 

and Daimler Chrysler; Blue Cross/Blue 

Shield of Michigan; Henry Ford Health 

System/Health Alliance Plan; Health 

Plus of Michigan; SureScripts, RxHub 

and MedCo. This is a unique project in 

terms of size, sponsoring organizations, 

patient base, geographic area, and 

approach. This project is consistent 

with CMS’ goals to improve health care 

quality, patient safety, and the use of 

electronic prescribing. Funding of this 

unsolicited proposal will result in a 

desirable public benefit in that its aim 

is to provide needed information on the 

costs and critical success factors 

associated with the adoption of 

electronic prescribing, as well as to 

provide improvements in quality and 

safety of care delivery. 

FOR FURTHER INFORMATION CONTACT: 

Maria Friedman, Project Officer, Office 

of e-health Standards and Services, 

Centers for Medicare and Medicaid 

Services, 7500 Security Blvd., Stop S2–

27–17, Baltimore, MD 21244, (410) 786–

6333 or Judy Norris, Grants Officer, 

Department of Health and Human 

Services, OOM/AGG/CMS, 7500 

Security Blvd., Stop S2–21–15, 

Baltimore, MD 21244, (410) 786–5130. 

Authority: Catalog of Federal Domestic 

Assistance Program No. 93–779, Center for 

Medicare and Medicaid Services, Research, 

Demonstrations and Evaluations; Section 

1110 of the Social Security Act. 

Dated: August 9, 2005. 

Mark B. McClellan, 

Administrator, Centers for Medicare and 

Medicaid Services. 

[FR Doc. 05–21731 Filed 10–31–05; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Submission for OMB Review; 

Comment Request 

Title: The National Evaluation of the 

Court Improvement Program. 

OMB No.: New Collection. 

Description: The National Evaluation 

of the Court Improvement Program will 

describe the many paths followed by 

state courts to improve their oversight of 

child welfare cases, and will provide the 

field with information on effective 

models for juvenile and family court 

reform. Funded by the Children’s 

Bureau, U.S. Department of Health and 

Human Services (HHS) in 2004, the fiveyear study is being carried out by a 

partnership of three organizations 

consisting of Planning and Learning 

Technologies (Pal-Tech, Inc.), the Urban 

Institute and the Center for Policy 

Research.